Ac-225 Rosopatamab Tetraxetan
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Ac-225 Rosopatamab Tetraxetan, covering 2025-08-24 to 2025-08-24. Get the full timeline:
Most recent: Clinical Trial Update: Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC) [Phase 2]